Online inquiry

IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15348MR)

This product GTTS-WQ15348MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ENG gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000118.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2022
UniProt ID P17813
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15348MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10305MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ5377MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ8067MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ4320MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ7117MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ4604MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ7348MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ3336MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW